Fred D Lublin

List of Publications by Year in descending order

90 papers	20,542 citations	172457 29 h-index	51608 86 g-index
91 all docs	91 docs citations	91 times ranked	15528 citing authors

#	Article	IF	Citations
1	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 2001, 50, 121-127.	5.3	6,122
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
3	New Multiple Sclerosis Phenotypic Classification. European Neurology, 2014, 72, 1-5.	1.4	3,135
4	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
5	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) Tj ETQq1 1 0.784314 rgBT /Over 545-556.	10.2	707
6	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
7	Effect of relapses on development of residual deficit in multiple sclerosis. Neurology, 2003, 61, 1528-1532.	1.1	394
8	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084.	13.7	379
9	Clinical Course of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a028928.	6.2	186
10	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology, 2013, 73, 327-340.	5.3	182
11	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	9.0	132
12	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	7.6	126
13	Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology, 2014, 83, 78-86.	1.1	115
14	Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. Multiple Sclerosis and Related Disorders, 2014, 3, 696-704.	2.0	102
15	Clinical features and diagnosis of multiple sclerosis. Neurologic Clinics, 2005, 23, 1-15.	1.8	82
16	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.1	73
17	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. Radiology, 2020, 294, 398-404.	7.3	67
18	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64

#	ARTICLE	IF	CITATIONS
19	Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. Annals of Neurology, 2001, 49, 677-681.	5.3	52
20	Cerebellar lobule atrophy and disability in progressive MS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1065-1072.	1.9	47
21	History of modern multiple sclerosis therapy. Journal of Neurology, 2005, 252, iii3-iii9.	3.6	46
22	Disease activity free status in MS. Multiple Sclerosis and Related Disorders, 2012, 1, 6-7.	2.0	43
23	Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain, 2015, 138, 517-539.	7.6	41
24	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal, 2018, 24, 1469-1484.	3.0	41
25	Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?. Multiple Sclerosis Journal, 2017, 23, 43-50.	3.0	40
26	Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma. Brain, 2022, 145, 569-583.	7.6	40
27	Relapses in multiple sclerosis: Relationship to disability. Multiple Sclerosis and Related Disorders, 2016, 6, 10-20.	2.0	36
28	Novel Agents for Relapsing Forms of Multiple Sclerosis. Annual Review of Medicine, 2016, 67, 309-321.	12.2	35
29	Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1247-1255.	3.0	35
30	Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1752-1764.	3.0	34
31	Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. JAMA Neurology, 2015, 72, 1466.	9.0	32
32	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
33	Regional gray matter atrophy in relapsing remitting multiple sclerosis: Baseline analysis of multi-center data. Multiple Sclerosis and Related Disorders, 2015, 4, 124-136.	2.0	31
34	Deep‐Learning‐Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size. Journal of Magnetic Resonance Imaging, 2020, 51, 1487-1496.	3.4	31
35	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 2014, 3, 705-711.	2.0	30
36	Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. Journal of Neurology, 2016, 263, 354-360.	3.6	30

#	Article	IF	Citations
37	Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain, 2019, 142, 2722-2736.	7.6	30
38	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.1	28
39	Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis. Scientific Reports, 2017, 7, 46411.	3.3	27
40	The incomplete nature of multiple sclerosis relapse resolution. Journal of the Neurological Sciences, 2007, 256, S14-S18.	0.6	26
41	Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space. Current Neurology and Neuroscience Reports, 2016, 16, 90.	4.2	25
42	Detection of subtle gait disturbance and future fall risk in early multiple sclerosis. Neurology, 2020, 94, e1395-e1406.	1.1	25
43	Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1111-1120.	3.0	23
44	Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e441.	6.0	22
45	Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096901.	3.5	20
46	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e1560-e1570.	1.1	19
47	Cerebellar volume as imaging outcome in progressive multiple sclerosis. PLoS ONE, 2017, 12, e0176519.	2.5	19
48	Multiple sclerosis trial designs for the 21st century: Building on recent lessons. Journal of Neurology, 2005, 252, v46-v53.	3.6	18
49	A clinically feasible 7-Tesla protocol for the identification of cortical lesions in Multiple Sclerosis. European Radiology, 2020, 30, 4586-4594.	4.5	18
50	Brain microstructural injury occurs in patients with RRMS despite â€˜no evidence of disease activityâ€™. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 977-982.	1.9	16
51	Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. Multiple Sclerosis and Related Disorders, 2021, 56, 103229.	2.0	16
52	When marketing and science intersect. Neurology, 2002, 59, 1480-1481.	1.1	15
53	The diagnosis of multiple sclerosis. Current Opinion in Neurology, 2002, 15, 253-256.	3.6	15
54	Relapses do not matter in relation to long-term disability: No (they do). Multiple Sclerosis Journal, 2011, 17, 1415-1416.	3.0	15

#	ARTICLE	IF	CITATIONS
55	Effect of inâ€painting on cortical thickness measurements in multiple sclerosis: A large cohort study. Human Brain Mapping, 2015, 36, 3749-3760.	3.6	15
56	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. Multiple Sclerosis and Related Disorders, 2017, 18, 95-102.	2.0	15
57	Magnetic Resonance Imaging of Meningoradiculomyelitis in Early Disseminated Lyme Disease. Journal of Neuroimaging, 2003, 13, 264-268.	2.0	13
58	Emergency Medical Care of Multiple Sclerosis Patients: Primary Data from the Mount Sinai Resource		

#	Article	IF	Citations
73	Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 568-578.	3.0	6
74	Optic neuropathy in late-onset neurodegenerative Chédiak–Higashi syndrome. British Journal of Ophthalmology, 2016, 100, 704-707.	3.9	5
75	061…Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.2-A25.	1.9	5
76	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	1.6	4
77	A composite measure to explore visual disability in primary progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731770962.	1.0	3
78	PO129…Neda analysis by epoch in the opera studies of ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.2-A46.	1.9	3
79	Objective and subjective measures of dalfampridine efficacy in clinical practice. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878674.	1.0	3
80	Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. Multiple Sclerosis and Related Disorders, 2021, 49, 102715.	2.0	3
81	Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerations. Annals of Neurology, 2001, 49, 677-681.	5.3	3
82	MS as a gateway disease. Journal of the Neurological Sciences, 2013, 333, 73-75.	0.6	1
83	William Austin Sibley, MD (1925–2015). Multiple Sclerosis Journal, 2016, 22, 11-12.	3.0	1
84	Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: a retrospective analysis from the CombiRx trial. European Journal of Neurology, 2021, 29, 515.	3.3	1
85	Early first‐line treatment response and subsequent disability worsening in relapsing–remitting multiple sclerosis. European Journal of Neurology, 2022, 29, 1106-1116.	3.3	1
86	Multiple Sclerosis as a Model Neurologic Disease. Mount Sinai Journal of Medicine, 2011, 78, 159-160.	1.9	0
87	Editorial. Multiple Sclerosis and Related Disorders, 2013, 2, 153.	2.0	0
88	Multiple Sclerosis and Other Inflammatory Diseases. , 2016, , 249-258.		0
89	PO128…Infusion-related reactions with ocrelizumab in rms and ppms. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.1-A46.	1.9	0
90	Real-world studies provide reliable comparisons of disease modifying therapies in MS – Commentary. Multiple Sclerosis Journal, 2020, 26, 163-164.	3.0	0